Named Bioactive Compounds · Compound
Cinnamaldehyde (Phenylpropanoid)
Strong Evidencephenolic_compound
Hermetica Superfood Encyclopedia
Cinnamaldehyde is a phenylpropanoid compound found in cinnamon that provides anti-inflammatory and glucose-regulating effects. It works primarily through TRPA1 channel activation and inhibition of inflammatory pathways including NF-κB signaling.
Cinnamaldehyde is a bioactive phytochemical isolated from the stem bark of cinnamon, a traditional Chinese herbal medicine. It belongs to the phenylpropanoid class of compounds and is extracted from cinnamon plant material through standard phytochemical isolation procedures.
Limited human clinical evidence exists, with one randomized controlled trial (PMID: 35701773) showing significant reduction in oral ulcer size and pain. Most research consists of animal studies demonstrating effects on diabetes (PMID: 39543757, 33453370), arthritis (PMID: 32029577), and obesity (PMID: 28719892). Human studies have also shown increased energy expenditure with acute ingestion.
Animal studies have used 20-75 mg/kg/day orally. Human clinical trials have utilized mucoadhesive patches for oral conditions, though specific dosing was not detailed. No standardized human dosing guidelines are established. Consult a healthcare provider before starting any new supplement.
Cinnamaldehyde is a pure bioactive phenylpropanoid compound (C9H8O, molecular weight 132.16 g/mol), not a whole food, so conventional macronutrient/micronutrient framing does not apply. Key compositional facts: it is the primary volatile aldehyde constituent of cinnamon bark essential oil, typically comprising 55–90% of cinnamon bark oil by weight (varies by species: Cinnamomum verum ~55–75%, C. cassia ~73–90%). As an isolated compound, it contains no fiber, protein, vitamins, or minerals. Bioactive profile: it is a α,β-unsaturated aldehyde with a trans (E) configuration, enabling electrophilic reactivity with biological nucleophiles (e.g., cysteine thiols, lysine residues), which underlies many of its pharmacological effects. Typical concentration in whole cinnamon bark powder ranges from approximately 0.5–4% by dry weight. Bioavailability notes: orally administered cinnamaldehyde undergoes rapid first-pass metabolism; it is quickly converted to cinnamic acid and cinnamyl alcohol via aldehyde oxidase and aldo-keto reductases in intestinal and hepatic tissues, with detectable plasma metabolites within 30–60 minutes post-ingestion. Absolute oral bioavailability of the parent compound is low due to this rapid biotransformation; metabolites (particularly cinnamic acid) contribute to systemic activity. Lipophilicity (log P ≈ 1.9) facilitates membrane permeability. No significant caloric density attributable to physiological doses used therapeutically (typically 50–500 mg/day in human studies).
Cinnamaldehyde activates TRPA1 (transient receptor potential ankyrin 1) channels, which contributes to its anti-inflammatory effects. It also inhibits NF-κB signaling pathways and modulates glucose metabolism by enhancing insulin sensitivity and reducing oxidative stress markers. The compound's phenolic structure allows it to scavenge free radicals and protect against cellular damage.
One randomized controlled trial demonstrated that cinnamaldehyde significantly reduced oral ulcer size and pain in patients with recurrent aphthous stomatitis, showing moderate clinical evidence. Animal studies suggest potential benefits for diabetic nephropathy, with improvements in blood glucose, HbA1c levels, and kidney function markers. However, human clinical data for diabetes management remains limited to preliminary research. Most evidence comes from in vitro and animal studies, requiring more robust human trials to confirm therapeutic efficacy.
Cinnamaldehyde is generally recognized as safe when consumed in typical food amounts, but concentrated supplements may cause oral irritation or allergic reactions in sensitive individuals. It may enhance the effects of diabetes medications, potentially leading to hypoglycemia when combined with insulin or sulfonylureas. Topical applications can cause contact dermatitis in some people. Pregnancy and breastfeeding safety data is insufficient, so supplemental doses should be avoided during these periods.
